Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
暂无分享,去创建一个
H. Hartung | B. Hemmer | R. Gold | S. Zamvil | J. Bennett | E. Frohman | B. Kieseier | M. Racke | C. Warnke | O. Stüve | B. Greenberg | T. Menge | P. Cravens | J. Bennett
[1] B. P. Hernández,et al. JC Virus infection of the brain , 2012 .
[2] D. Clifford,et al. Progressive multifocal leukoencephalopathy in transplant recipients , 2011, Annals of neurology.
[3] I. Koralnik,et al. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis , 2010, The Lancet Neurology.
[4] G. Pantaleo,et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study , 2010, The Lancet Neurology.
[5] R. Bergamaschi,et al. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? , 2009, Multiple sclerosis.
[6] I. Koralnik,et al. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression , 2009, Journal of Neurology, Neurosurgery & Psychiatry.
[7] J. Miro,et al. Progressive multifocal leukoencephalopathy in HIV-1 infection. , 2009, The Lancet. Infectious diseases.
[8] D. Clifford,et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. , 2009, The New England journal of medicine.
[9] E. Major. Reemergence of PML in natalizumab-treated patients--new cases, same concerns. , 2009, The New England journal of medicine.
[10] E. Major,et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. , 2009, The New England journal of medicine.
[11] L. Ngo,et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. , 2009, The New England journal of medicine.
[12] David Green,et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. , 2009, Blood.
[13] J. McArthur,et al. PML-IRIS in patients with HIV infection , 2009, Neurology.
[14] J. Berger. Steroids for PML-IRIS , 2009, Neurology.
[15] I. Koralnik,et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. , 2009, The Journal of infectious diseases.
[16] Adrian Egli,et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. , 2009, The Journal of infectious diseases.
[17] K. Simon,et al. Identification and Characterization of Mefloquine Efficacy against JC Virus In Vitro , 2009, Antimicrobial Agents and Chemotherapy.
[18] R. Garcea,et al. Seroepidemiology of Human Polyomaviruses , 2009, PLoS pathogens.
[19] C. Polman,et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study , 2009, The Lancet Neurology.
[20] R. Ransohoff,et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function , 2009, Neurology.
[21] D. Miller,et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy , 2009, Neurology.
[22] C. Ryschkewitsch,et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA , 2009, Multiple sclerosis.
[23] B. Hemmer,et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. , 2008, Archives of neurology.
[24] E. Major,et al. Response to Linberg et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients , 2008, Journal of Neuroimmunology.
[25] S. Croul,et al. Detection of JC virus DNA fragments but not proteins in normal brain tissue , 2008, Annals of neurology.
[26] K. Khalili,et al. Potential Mechanisms of the Human Polyomavirus JC in Neural Oncogenesis , 2008, Journal of neuropathology and experimental neurology.
[27] E. Frohman,et al. Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients , 2008, PloS one.
[28] P. Rutgeerts,et al. JC viral loads in patients with Crohn’s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? , 2008, Gut.
[29] H. Hartung,et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. , 2008, Blood.
[30] Kai-Hsin Chang,et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. , 2008, Blood.
[31] P. Randhawa,et al. Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. , 2008, American journal of clinical pathology.
[32] F. Barkhof,et al. POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS , 2008, Neurology.
[33] P. Moore,et al. Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma , 2008, Science.
[34] M. Atkins,et al. Melanoma complicating treatment with natalizumab for multiple sclerosis. , 2008, The New England journal of medicine.
[35] L. Kappos,et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients , 2008, Journal of Neuroimmunology.
[36] L. Kappos,et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring , 2007, The Lancet Neurology.
[37] Ludwig Kappos,et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.
[38] D. Brennan,et al. Identification of a Novel Polyomavirus from Patients with Acute Respiratory Tract Infections , 2007, PLoS pathogens.
[39] Hans Lassmann,et al. The Immunopathology of Multiple Sclerosis: An Overview , 2007, Brain pathology.
[40] Tobias Allander,et al. Identification of a Third Human Polyomavirus , 2007, Journal of Virology.
[41] H. Hartung,et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. , 2007, Archives of neurology.
[42] P. Dazin,et al. Apoptotic effects of Human Herpesvirus-6A on glia and neurons as potential triggers for central nervous system autoimmunity. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[43] A. Bar-Or,et al. Altered CD 4 / CD 8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis , 2006 .
[44] S. Cepok,et al. Immune surveillance in multiple sclerosis patients treated with natalizumab , 2006, Annals of neurology.
[45] J. Bennett,et al. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis , 2006, Neurological research.
[46] K. Khalili,et al. Human demyelinating disease and the polyomavirus JCV , 2006, Multiple sclerosis.
[47] Christian Confavreux,et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[48] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[49] F. Barkhof,et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. , 2006, The New England journal of medicine.
[50] R. Alon,et al. Immune cell migration in inflammation: present and future therapeutic targets , 2005, Nature Immunology.
[51] R. Ransohoff. Natalizumab and PML , 2005, Nature Neuroscience.
[52] S. Jacobson,et al. Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes , 2005, Journal of NeuroVirology.
[53] E. Major,et al. Variant-Specific Tropism of Human Herpesvirus 6 in Human Astrocytes , 2005, Journal of Virology.
[54] S. Jacobson,et al. Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease. , 2005, Herpes : the journal of the IHMF.
[55] C. Drachenberg,et al. Successful Outcome of Progressive Multifocal Leukoencephalopathy in a Renal Transplant Patient , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[56] Jean Hou,et al. Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories , 2005, International journal of cancer.
[57] H. Tremlett. Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects , 2005, Neurology.
[58] D. Boutolleau,et al. Reactivation of human herpesvirus 6 during ex vivo expansion of circulating CD34+ haematopoietic stem cells. , 2004, The Journal of general virology.
[59] M. Kuroda,et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. , 2004, Brain : a journal of neurology.
[60] L. Lindbom,et al. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. , 2003, Trends in pharmacological sciences.
[61] M. Kuroda,et al. Low Frequency of Cytotoxic T Lymphocytes against the Novel HLA-A*0201-Restricted JC Virus Epitope VP1p36 in Patients with Proven or Possible Progressive Multifocal Leukoencephalopathy , 2003, Journal of Virology.
[62] N. Andrews,et al. Population‐based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40 , 2003, Journal of medical virology.
[63] J. Delfraissy,et al. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy , 2003, AIDS.
[64] D. Pierson,et al. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. , 2003, The Journal of infectious diseases.
[65] David H. Miller,et al. A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.
[66] B. Engelhardt,et al. Alpha4 integrins as therapeutic targets in autoimmune disease. , 2003, The New England journal of medicine.
[67] J. Schmitz,et al. Association of Prolonged Survival in HLA-A2+ Progressive Multifocal Leukoencephalopathy Patients with a CTL Response Specific for a Commonly Recognized JC Virus Epitope1 , 2002, The Journal of Immunology.
[68] M. Zöller,et al. Combining G-CSF with a blockade of adhesion strongly improves the reconstitutive capacity of mobilized hematopoietic progenitor cells. , 2001, Experimental hematology.
[69] M. Lichterfeld,et al. Mobilization of CD34+ haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4 , 2000, British journal of haematology.
[70] J. Parisi,et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.
[71] W. Atwood,et al. JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. , 2000, Journal of neurovirology.
[72] E. Leung,et al. β7 integrins contribute to demyelinating disease of the central nervous system , 2000, Journal of Neuroimmunology.
[73] Jacqueline Palace,et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS , 1999, Neurology.
[74] D. MacManus,et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. , 1999, Neurology.
[75] R. Pardi,et al. Regulation of lymphocyte traffic by adhesion molecules , 1999, Inflammation Research.
[76] M. Koller,et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS , 1999, Neurology.
[77] C. Morris,et al. Human Herpesvirus 6 Latently Infects Early Bone Marrow Progenitors In Vivo , 1999, Journal of Virology.
[78] E. Major,et al. Detection of JC Virus DNA in Human Tonsil Tissue: Evidence for Site of Initial Viral Infection , 1998, Journal of Virology.
[79] M. Yamaguchi,et al. Different adhesive characteristics and VLA-4 expression of CD34(+) progenitors in G0/G1 versus S+G2/M phases of the cell cycle. , 1998, Blood.
[80] C. Craddock,et al. Antibodies to VLA4 Integrin Mobilize Long-Term Repopulating Cells and Augment Cytokine-Induced Mobilization in Primates and Mice , 1997 .
[81] G. Tjønnfjord,et al. Efflux of CD34+ cells from bone marrow to peripheral blood is selective in steady-state hematopoiesis and during G-CSF administration. , 1997, Journal of hematotherapy.
[82] W. Heath,et al. Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.
[83] H. Ebihara,et al. Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains , 1997, Journal of clinical microbiology.
[84] E. Major,et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency , 1996, Journal of virology.
[85] P. Cinque,et al. JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[86] T. Papayannopoulou,et al. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[87] M. Post,et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. , 1993, Radiology.
[88] B. Padgett,et al. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. , 1973, The Journal of infectious diseases.
[89] D. Coleman,et al. New human papovavirus (B.K.) isolated from urine after renal transplantation. , 1971, Lancet.
[90] B. Padgett,et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. , 1971, Lancet.
[91] E. Mancall. Progressive multifocal leukoencephalopathy , 1965, Neurology.
[92] E. Richardson. Progressive multifocal leukoencephalopathy. , 1961, The New England journal of medicine.
[93] E. Mancall,et al. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. , 1958, Brain : a journal of neurology.
[94] N. Letvin,et al. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy , 2011, Journal of NeuroVirology.
[95] H. McFarland. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab , 2009 .
[96] R. Lonergan,et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. , 2009, The New England journal of medicine.
[97] J. Stockman. Progressive Multifocal Leukoencephalopathy Complicating Treatment With Natalizumab and Interferon Beta-1a for Multiple Sclerosis , 2007 .
[98] A. Verma. Progressive Multifocal Leukoencephalopathy in a Patient Treated With Natalizumab , 2006 .
[99] W. Knowles. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). , 2006, Advances in experimental medicine and biology.
[100] G. Lichtenstein. Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohn's Disease , 2006 .
[101] T. Papayannopoulou,et al. Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm. , 2000, Seminars in hematology.
[102] E. Leung,et al. Beta7 integrins contribute to demyelinating disease of the central nervous system. , 2000, Journal of neuroimmunology.
[103] G Leone,et al. Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF , 1999, Bone Marrow Transplantation.
[104] J. Assouline,et al. Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathy. , 1999, Journal of neurovirology.
[105] C. Craddock,et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. , 1997, Blood.
[106] F. Sánchez‐Madrid,et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. , 1992, Nature.
[107] D. McFarlin,et al. Immunological aspects of demyelinating diseases. , 1992, Annual review of immunology.